ABCL · Categories · Offerings
ABCL - Public offerings
AbCellera Biologics Inc. (ABCL) public offerings - real-time wire coverage filtered to Offerings only.
Recent Offerings for ABCL
- AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded WarrantsAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant, which represents the per share public offering price of each common share less the $0.00001 per share exercise price for each pre-funded warrant. The gross proceeds to AbCellera from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and e
- AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsAbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. AbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipelin
- AbCellera Appoints Dr. Sarah Noonberg as Chief Medical OfficerAbCellera (NASDAQ:ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist, brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization across a diverse range of indications and therapeutic modalities, including oncology, neuroscience, rare diseases, gene therapy, and cell therapy. As Chief Medical Officer, Dr. Noonberg, will leverage her clinical development background to advance AbCellera's pipeline of antibody-based therapeutics. "We are pleased to welcome Sarah as AbCellera's first Chief Medical Officer,"
- AbCellera Announces Secondary Private Sale of 11.9 Million Common SharesVANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors (the “Buyers”), pursuant to which the Buyers purchased an aggregate 11,900,000 common shares (“Shares”). Proceeds from the sale were paid to the Selling Shareholders, and AbCellera did not receive any proceeds. Dr. Hansen’s sale was in connection with estate planning, technology in
- AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesVANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Biologics Inc. (“AbCellera”) (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the public of $20.00 per share, which includes the exercise in full of the underwriters’ option to purchase 3,622,500 additional common shares. All of the common shares were offered by AbCellera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $555.5 million. In addition, upon
Other ABCL categories
Is something on this page wrong? Request a change